ERBB2 and glioblastoma: Clinical trials with CAR-T cells targeting interleukin(IL)-13Rα2, epidermal growth factor receptor variant III (EGFRvIII), and human epidermal growth factor receptor 2 (HER2) for GBM treatment have been completed [16–18].